1. Figure 2 Survival curves in the elderly vs. younger patients
Figure 2 Survival curves in the elderly vs. younger patients. (A) Outcome. (B) Severe bleeding events. SE, standard error; n, number of ITT patients at risk.
From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial
Eur Heart J. 2006;28(8): doi: /eurheartj/ehl364
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

2. Figure 3 Relative effect on vascular events. (A) The elderly vs
Figure 3 Relative effect on vascular events. (A) The elderly vs. younger group. (B) Combined vs. anticoagulant therapy. The hazard ratio (HR) = logarithm hazard ratio whose 95% (error bars) excludes the vertical line are statistically significant at the 5% level.
From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial
Eur Heart J. 2006;28(8): doi: /eurheartj/ehl364
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

3. Figure 4 Outcome survival curves during combined and anticoagulant therapy. (A) The elderly patients. (B) Younger patients. n, ITT patients at risk.
From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial
Eur Heart J. 2006;28(8): doi: /eurheartj/ehl364
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

4. Figure 1 Flow chart of NASPEAF patients
Figure 1 Flow chart of NASPEAF patients. ITT corresponds to patients of whom efficacy and safety data are available. IQR_P25–P75, interquartile range; anticoagulant therapy, INR range of 2.0–3.0. Combined therapy, triflusal 600 mg/day plus anticoagulation for a median INR of 1.97–2.17.
From: Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial
Eur Heart J. 2006;28(8): doi: /eurheartj/ehl364
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please